PMV Pharmaceuticals Statistics
Total Valuation
PMVP has a market cap or net worth of $63.46 million. The enterprise value is -$29.79 million.
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PMVP has 53.33 million shares outstanding. The number of shares has increased by 2.28% in one year.
| Current Share Class | 53.33M |
| Shares Outstanding | 53.33M |
| Shares Change (YoY) | +2.28% |
| Shares Change (QoQ) | +0.25% |
| Owned by Insiders (%) | 3.37% |
| Owned by Institutions (%) | 54.76% |
| Float | 43.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.72 |
| P/TBV Ratio | 0.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.14, with a Debt / Equity ratio of 0.00.
| Current Ratio | 11.14 |
| Quick Ratio | 10.88 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -63.16% and return on invested capital (ROIC) is -41.92%.
| Return on Equity (ROE) | -63.16% |
| Return on Assets (ROA) | -39.14% |
| Return on Invested Capital (ROIC) | -41.92% |
| Return on Capital Employed (ROCE) | -95.10% |
| Weighted Average Cost of Capital (WACC) | 11.65% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.45M |
| Employee Count | 54 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, PMVP has paid $25,000 in taxes.
| Income Tax | 25,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9.17% in the last 52 weeks. The beta is 1.36, so PMVP's price volatility has been higher than the market average.
| Beta (5Y) | 1.36 |
| 52-Week Price Change | +9.17% |
| 50-Day Moving Average | 1.27 |
| 200-Day Moving Average | 1.30 |
| Relative Strength Index (RSI) | 51.26 |
| Average Volume (20 Days) | 291,117 |
Short Selling Information
The latest short interest is 3.26 million, so 6.10% of the outstanding shares have been sold short.
| Short Interest | 3.26M |
| Short Previous Month | 3.08M |
| Short % of Shares Out | 6.10% |
| Short % of Float | 7.55% |
| Short Ratio (days to cover) | 8.43 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -83.66M |
| Pretax Income | -78.32M |
| Net Income | -78.34M |
| EBITDA | -83.53M |
| EBIT | -83.66M |
| Earnings Per Share (EPS) | -$1.48 |
Full Income StatementBalance Sheet
The company has $93.55 million in cash and $293,000 in debt, giving a net cash position of $93.26 million or $1.75 per share.
| Cash & Cash Equivalents | 93.55M |
| Total Debt | 293,000 |
| Net Cash | 93.26M |
| Net Cash Per Share | $1.75 |
| Equity (Book Value) | 87.97M |
| Book Value Per Share | 1.65 |
| Working Capital | 87.19M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$74.99 million and capital expenditures -$25,000, giving a free cash flow of -$75.02 million.
| Operating Cash Flow | -74.99M |
| Capital Expenditures | -25,000 |
| Depreciation & Amortization | 130,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -75.02M |
| FCF Per Share | -$1.41 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |